Newbridge Financial Services Group’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.7K | Hold |
700
| – | – | ﹤0.01% | 844 |
|
|
2025
Q1 | $10.8K | Hold |
700
| – | – | ﹤0.01% | 667 |
|
|
2024
Q4 | $15.4K | Buy |
+700
| New | +$15.4K | ﹤0.01% | 658 |
|
|
2024
Q3 | – | Sell |
-900
| Closed | -$14.6K | – | 1070 |
|
|
2024
Q2 | $14.6K | Hold |
900
| – | – | 0.01% | 638 |
|
|
2024
Q1 | $12.7K | Sell |
900
-7,000
| -89% | -$98.8K | 0.01% | 708 |
|
|
2023
Q4 | $82.5K | Buy |
+7,900
| New | +$82.5K | 0.04% | 305 |
|
|
2023
Q3 | – | Sell |
-9,900
| Closed | -$74.5K | – | 1399 |
|
|
2023
Q2 | $74.5K | Hold |
9,900
| – | – | 0.04% | 364 |
|
|
2023
Q1 | $87.6K | Hold |
9,900
| – | – | 0.05% | 342 |
|
|
2022
Q4 | $90.3K | Buy |
9,900
+4,000
| +68% | +$36.5K | 0.05% | 320 |
|
|
2022
Q3 | $48K | Buy |
5,900
+5,000
| +556% | +$40.7K | 0.03% | 464 |
|
|
2022
Q2 | $7K | Buy |
900
+200
| +29% | +$1.56K | ﹤0.01% | 953 |
|
|
2022
Q1 | $7K | Hold |
700
| – | – | ﹤0.01% | 1032 |
|
|
2021
Q4 | $6K | Sell |
700
-2,000
| -74% | -$17.1K | ﹤0.01% | 1043 |
|
|
2021
Q3 | $26K | Buy |
2,700
+900
| +50% | +$8.67K | 0.02% | 592 |
|
|
2021
Q2 | $18K | Buy |
1,800
+1,100
| +157% | +$11K | 0.01% | 810 |
|
|
2021
Q1 | $8K | Sell |
700
-236
| -25% | -$2.7K | 0.01% | 963 |
|
|
2020
Q4 | $9K | Hold |
936
| – | – | 0.01% | 755 |
|
|
2020
Q3 | $8K | Buy |
+936
| New | +$8K | 0.01% | 734 |
|